Preclinical cell line models of ER+ breast cancer have revealed that HER2 overexpression or HER family activation via addition of recombinant heregulin β1—a HER family ligand—resulted in attenuated ER expression, with no impact on intrinsic estradiol-binding affinity to the ER by Scatchard analysis36. Here, ERBB2 is linked to breast carcinoma.